IL325202A - Antibodies against fibers (fibrils) - Google Patents

Antibodies against fibers (fibrils)

Info

Publication number
IL325202A
IL325202A IL325202A IL32520225A IL325202A IL 325202 A IL325202 A IL 325202A IL 325202 A IL325202 A IL 325202A IL 32520225 A IL32520225 A IL 32520225A IL 325202 A IL325202 A IL 325202A
Authority
IL
Israel
Prior art keywords
seq
monoclonal antibody
domain
sequence identity
humanised
Prior art date
Application number
IL325202A
Other languages
English (en)
Hebrew (he)
Original Assignee
Immutrin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2308898.2A external-priority patent/GB202308898D0/en
Priority claimed from GBGB2308884.2A external-priority patent/GB202308884D0/en
Application filed by Immutrin Ltd filed Critical Immutrin Ltd
Publication of IL325202A publication Critical patent/IL325202A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL325202A 2023-06-14 2024-06-13 Antibodies against fibers (fibrils) IL325202A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2308898.2A GB202308898D0 (en) 2023-06-14 2023-06-14 Anti-fibril antibodies
GBGB2308884.2A GB202308884D0 (en) 2023-06-14 2023-06-14 Anti-fibril antibodies
PCT/EP2024/066449 WO2024256583A1 (fr) 2023-06-14 2024-06-13 Anticorps anti-fibrilles

Publications (1)

Publication Number Publication Date
IL325202A true IL325202A (en) 2026-02-01

Family

ID=91580895

Family Applications (1)

Application Number Title Priority Date Filing Date
IL325202A IL325202A (en) 2023-06-14 2024-06-13 Antibodies against fibers (fibrils)

Country Status (9)

Country Link
EP (1) EP4727650A1 (fr)
JP (1) JP2026520213A (fr)
KR (1) KR20260026033A (fr)
CN (1) CN121487964A (fr)
AU (1) AU2024304161A1 (fr)
CL (1) CL2025003893A1 (fr)
IL (1) IL325202A (fr)
MX (1) MX2025014924A (fr)
WO (1) WO2024256583A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202418667D0 (en) * 2024-12-19 2025-02-05 Immutrin Ltd Anti-fibril antibodies with engineered Fc regions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1991000906A1 (fr) 1989-07-12 1991-01-24 Genetics Institute, Inc. Animaux chimeriques et transgeniques pouvant produire des anticorps humains
CA2090473A1 (fr) 1990-08-29 1992-03-01 Robert M. Kay Recombinaison homologue dans des cellules mammaliennes
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
EP1972194A1 (fr) 1996-12-03 2008-09-24 Amgen Fremont Inc. Mammifères transgéniques disposant d'un loci ig comprenant plusieurs régions vh et vk et anticorps produits à partir de ceux-ci
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6475220B1 (en) 1999-10-15 2002-11-05 Whiteside Biomechanics, Inc. Spinal cable system
PE20161093A1 (es) * 2013-12-20 2016-10-23 Neurimmune Holding Ag Terapia basada en anticuerpos de amiloidosis por transtiretina (ttr) y anticuerpos derivados de humanos de la misma
CN106574258B (zh) * 2014-01-29 2021-03-30 Km生物医药股份公司 抗-运甲状腺素蛋白人源化抗体
SG11202002489YA (en) * 2017-10-06 2020-04-29 Prothena Biosciences Ltd Anti-transthyretin antibodies
WO2022094152A1 (fr) * 2020-10-28 2022-05-05 Neotope Neuroscience Limited Anticorps anti-transthyrétine et méthodes d'utilisation associées

Also Published As

Publication number Publication date
WO2024256583A1 (fr) 2024-12-19
MX2025014924A (es) 2026-02-03
EP4727650A1 (fr) 2026-04-22
CN121487964A (zh) 2026-02-06
AU2024304161A1 (en) 2025-12-11
CL2025003893A1 (es) 2026-01-30
JP2026520213A (ja) 2026-06-22
KR20260026033A (ko) 2026-02-25

Similar Documents

Publication Publication Date Title
CN110799531B (zh) 抗PHF-tau抗体及其用途
RU2770209C2 (ru) Терапевтические антитела против лиганда cd40
KR102866306B1 (ko) 신경 성장 인자에 대한 단일 클론 항체, 및 이의 코딩 유전자 및 용도
CN108350079B (zh) 用于治疗神经学和其它病症的结合激动剂
NZ717476A (en) Anti-garp protein and uses thereof
US20230174669A1 (en) Anti-CD98 Antibodies And Uses Thereof
US11440953B2 (en) Anti-abeta antibodies
AU2019395325B2 (en) Anti-Alpha-Synuclein Antibodies and Uses Thereof
CN120712286A (zh) 抗体、抗原结合片段和使用方法
WO2019001559A1 (fr) Anticorps anti-gitr, fragment de liaison à l'antigène de celui-ci et utilisation pharmaceutique associée
US20250101087A1 (en) Anti-amyloid beta antibodies and methods of using the same
JP2025525348A (ja) λサブクラスの免疫グロブリン軽鎖の立体配座特異的エピトープを標的とするモノクローナル抗体
WO2025117530A2 (fr) Anticorps se liant à des agrégats de tmem106b (120-254)
WO2025241702A1 (fr) Anticorps ciblant hla-g ou fragment de liaison à l'antigène de celui-ci et son utilisation
WO2026033259A1 (fr) Anticorps pour le traitement de troubles neurologiques et neurovasculaires
JP2024535691A5 (fr)
CN115443147A (zh) 抗体的皮下吸收和生物利用度
HK40054347B (en) Anti-alpha-synuclein antibodies and uses thereof
EA044828B1 (ru) Моноклональное антитело против фактора роста нервов, кодирующий его ген и его применение
HK1166331B (en) Use of an anti-tau ps422 antibody for the treatment of brain diseases
HK1166331A1 (en) Use of an anti-tau ps422 antibody for the treatment of brain diseases